192 related articles for article (PubMed ID: 36948846)
1. [Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].
; ;
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):16-34. PubMed ID: 36948846
[TBL] [Abstract][Full Text] [Related]
2. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
; ;
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy clinical application and research prospects for liver cancer].
Xia F; Chen XP
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):615-617. PubMed ID: 34371529
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).
Yang Y; Sun J; Wu M; Lau WY; Zheng S; Wang XH; Chen X; Fan J; Dong J; Cai J; Chen M; Chen Y; Cheng Z; Dai C; Shan J; Du CY; Fang C; Hu H; Ji Z; Jia W; Li G; Li J; Li J; Liu C; Liu F; Ma Y; Mao Y; Niu Z; Shen J; Shi J; Shi X; Song W; Sun HC; Tan G; Tao R; Wang X; Wen T; Wu L; Xia J; Xiang BD; Yan M; Ying M; Zhang L; Zhang X; Zeng ZC; Zhang Y; Zhang Z; Zhou J; Zhou C; Zhou J; Zhou L; Zhou X; Zhu J; Zhu Z; Zhang Q; Li Q; Cheng S
Liver Cancer; 2022 Dec; 11(6):511-526. PubMed ID: 36589726
[TBL] [Abstract][Full Text] [Related]
6. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition.
Cheng S; Chen M; Cai J;
Oncotarget; 2017 Jan; 8(5):8867-8876. PubMed ID: 27780939
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy-Based Treatments of Hepatocellular Carcinoma:
Cannella R; Lewis S; da Fonseca L; Ronot M; Rimola J
AJR Am J Roentgenol; 2022 Oct; 219(4):533-546. PubMed ID: 35506555
[TBL] [Abstract][Full Text] [Related]
8. [Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)].
; ;
Zhonghua Wai Ke Za Zhi; 2023 Dec; 61(12):1035-1045. PubMed ID: 37932138
[TBL] [Abstract][Full Text] [Related]
9. [Multidisciplinary experts consensus on diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2023 version)].
;
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1250-1261. PubMed ID: 38253068
[TBL] [Abstract][Full Text] [Related]
10. [Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage (2023 version)].
; ;
Zhonghua Gan Zang Bing Za Zhi; 2023 Sep; 31(9):910-920. PubMed ID: 37872086
[TBL] [Abstract][Full Text] [Related]
11. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: Current Status and Future Perspectives.
Floudas CS; Brar G; Greten TF
Dig Dis Sci; 2019 Apr; 64(4):1030-1040. PubMed ID: 30830521
[TBL] [Abstract][Full Text] [Related]
13. [Expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022)].
Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association
Zhonghua Wai Ke Za Zhi; 2022 Apr; 60(4):310-320. PubMed ID: 35272421
[TBL] [Abstract][Full Text] [Related]
14. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
15. [Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)].
Zhonghua Gan Zang Bing Za Zhi; 2020 Jan; 28(1):14-20. PubMed ID: 32023692
[TBL] [Abstract][Full Text] [Related]
16. [Emphasis on targeted and immunotherapy for liver injury in hepatocellular carcinoma].
Nan YM; Liu LD; Zhao SX
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1121-1124. PubMed ID: 38238942
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
18. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
Zhang DZ; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
[TBL] [Abstract][Full Text] [Related]
19. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.
Zhao HT; Cai JQ
World J Gastroenterol; 2021 Dec; 27(47):8069-8080. PubMed ID: 35068855
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in immunotherapy for hepatocellular carcinoma.
Khan AA; Liu ZK; Xu X
Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
